Methods: We reviewed our clinical results retrospectively in total of 14 patients with EAB grafting during the period between june 1995 to june 2001 in our clinic. 13 patients (92.8%) were male and only one patient was female, mean age was 58.4 ± 14 years. Axillobifemoral (AFF) bypass in 5 patients axillofemoral (AF) bypass in 2 patients, femoro-femoral (FF) bypass in 4 patients, axilloaxillary (AA) bypass in 2 patients, obturatory bypass (OB) in 1 patient were performed.

Results: Early mortality rate was 7.2% with one patient. In etiology, Takayasu’s arteritis exists in female patient, atherosclerosis exists in all of the male patients. EAB was performed as primary revascularization in 8 patients, as secondary revascularization in 6 patients. Total of 9 times various vascular interventions before EAB grafting operation were performed due to peripheral arterial occlusive disease in 6 patients. PTCA in 2 patients, CABG in 1 patient, CEA in 1 patient before EAB grafting operation were performed. Obturator bypass was performed due to graft infection in 1 patient with aorto-femoral bypass grafting. During the follow up period, 1 patient due to cerebrovascular event and 1 patient due to cardiac event died. We determined the graft thrombosis in 3 patients with AF, FF and AA bypass grafting. Secondary graft patency was provided through the embolectomy in only 1 patient with occluded graft.

Conclusion: EAB is the method of choice with reasonable mortality/morbidity rate, primary graft patency of 72.2% and patient’s survival of 78.5% in an avarage follow up of 2 years for high risk patient.